Royalty Pharma (RPRX) Interest Expenses (2019 - 2026)

Royalty Pharma has reported Interest Expenses for 8 years, with the latest figure at $223.6 million in Q1 2026.

• Quarterly Interest Expenses rose 22.52% year-over-year to $223.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $223.6 million (up 22.52% YoY) and the FY2025 annual result came in at $307.7 million, up 36.43% from the prior year.
• Interest Expenses improved to $223.6 million in Q1 2026 per RPRX's latest filing, from $38.1 million in the prior quarter.
• Over five years, Interest Expenses peaked at $223.6 million in Q1 2026 and troughed at -$198.9 million in Q1 2022.
• A 5-year average of $72.3 million and a median of $160.6 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses slumped 100.62% in 2024, then soared 21124.31% in 2025.
• Over 5 years, Interest Expenses stood at $663000.0 in 2022, then soared by 4309.65% to $29.2 million in 2023, then slumped by 100.62% to -$181000.0 in 2024, then jumped by 21124.31% to $38.1 million in 2025, then jumped by 487.59% to $223.6 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $223.6 million, $38.1 million, and $79.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.